Valbiotis Past Earnings Performance
Past criteria checks 0/6
Valbiotis's earnings have been declining at an average annual rate of -20.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 44.6% per year.
Key information
-20.4%
Earnings growth rate
5.1%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | 44.6% |
| Return on equity | -78.3% |
| Net Margin | -208.2% |
| Next Earnings Update | 29 Apr 2024 |
Revenue & Expenses BreakdownBeta
How Valbiotis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 4 | -9 | 5 | 10 |
| 31 Mar 23 | 3 | -11 | 6 | 10 |
| 31 Dec 22 | 1 | -12 | 6 | 9 |
| 30 Sep 22 | 1 | -11 | 5 | 9 |
| 30 Jun 22 | 1 | -10 | 5 | 9 |
| 31 Mar 22 | 1 | -9 | 4 | 8 |
| 31 Dec 21 | 0 | -9 | 4 | 7 |
| 30 Sep 21 | 2 | -7 | 4 | 6 |
| 30 Jun 21 | 3 | -4 | 3 | 6 |
| 31 Mar 21 | 3 | -4 | 3 | 6 |
| 31 Dec 20 | 3 | -4 | 3 | 5 |
| 30 Sep 20 | 2 | -5 | 3 | 5 |
| 30 Jun 20 | 0 | -6 | 3 | 4 |
| 31 Mar 20 | 0 | -6 | 3 | 4 |
| 31 Dec 19 | 0 | -6 | 3 | 4 |
| 30 Sep 19 | 0 | -6 | 3 | 4 |
| 30 Jun 19 | 0 | -6 | 3 | 5 |
| 31 Mar 19 | 0 | -5 | 3 | 4 |
| 31 Dec 18 | 0 | -5 | 3 | 4 |
| 30 Sep 18 | 0 | -4 | 2 | 3 |
| 30 Jun 18 | 0 | -4 | 2 | 3 |
| 31 Mar 18 | 0 | -3 | 2 | 2 |
| 31 Dec 17 | 0 | -2 | 2 | 2 |
| 30 Sep 17 | 0 | -2 | 1 | 1 |
| 30 Jun 17 | 0 | -1 | 1 | 1 |
| 31 Mar 17 | 0 | -1 | 1 | 1 |
| 31 Dec 16 | 0 | -1 | 0 | 1 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
Quality Earnings: ALVAL is currently unprofitable.
Growing Profit Margin: ALVAL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALVAL is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.
Accelerating Growth: Unable to compare ALVAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALVAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: ALVAL has a negative Return on Equity (-78.28%), as it is currently unprofitable.